Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted therapies, today announced that clinical data from its Phase 1 trial of CLN-619 in patients with advanced solid tumors will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from May 31-June 4, 2024.

Cullinan Therapeutics，Inc.（纳斯达克股票代码：CGEM）是一家专注于模式不可知靶向治疗的生物制药公司，今天宣布，其CLN-619晚期实体瘤患者1期临床试验的临床数据将于2024年5月31日至6月4日在芝加哥举行的2024年美国临床肿瘤学会（ASCO）年会上公布。

The data will include first results from the dose escalation cohort of CLN-619 in combination with checkpoint inhibitor pembrolizumab and updated results from the monotherapy dose escalation cohort in patients with advanced solid tumors.“We are pleased to present our initial clinical findings for CLN-619 plus pembrolizumab in patients with solid tumors at ASCO 2024, along with updated results from our monotherapy dose escalation study.

数据将包括CLN-619剂量递增队列与检查点抑制剂pembrolizumab联合的首次结果，以及晚期实体瘤患者单药治疗剂量递增队列的最新结果。“我们很高兴在ASCO 2024上介绍CLN-619加pembrolizumab治疗实体瘤患者的初步临床发现，以及我们单一疗法剂量递增研究的最新结果。

CLN-619 is a novel, potential first-in-class antibody that binds to MICA and MICB stress-induced ligands that engage the activating receptor NKG2D, present on both innate and adaptive immune cells. CLN-619 exerts its effects through multiple mechanisms, providing an opportunity to combine CLN-619 with immunotherapies that target potentially synergistic immune activation pathways, such as checkpoint inhibitors,” said Jeffrey Jones, MD, MPH, MBA, Chief Medical Officer, Cullinan Therapeutics.The details of the presentation include:Poster Title: CLN-619 (anti-MICA/B antibody) alone and in combination with pembrolizumab for advanced solid tumors: Updated results of a Ph1 studyAuthor:  Dr.

CLN-619是一种新型的，潜在的一流抗体，可与MICA和MICB应激诱导的配体结合，这些配体与先天性和适应性免疫细胞上存在的活化受体NKG2D结合。CLN-619通过多种机制发挥作用，为CLN-619与针对潜在协同免疫激活途径的免疫疗法（如检查点抑制剂）相结合提供了机会，”Cullinan Therapeutics首席医学官Jeffrey Jones说。演示的细节包括：海报标题：CLN-619（抗MICA/B抗体）单独和与pembrolizumab联合治疗晚期实体瘤：Ph1研究的最新结果作者：Dr。

Ignacio Melero, et al .Poster Number: 2588Session: Developmental Therapeutics—ImmunotherapySession Date and Time: June 1, 2024, 9:00 AM-12:00 PM Central TimeAbout CLN-619 CLN-619 is a potential first-in-class humanized IgG1 monoclonal antibody that binds to the stress induced ligands MICA and MICB.

Ignacio Melero等人。海报编号：2588会议：发育治疗学免疫治疗会议日期和时间：2024年6月1日上午9:00-下午12:00中央时间关于CLN-619 CLN-619是一种潜在的一流人源化IgG1单克隆抗体，可与应激诱导的配体MICA和MICB结合。